Compass Pathways
CMPS
NASDAQ
Biotech
Markets openAuto-updating · last checked
Clinical-stage biotech developing COMP360 synthetic psilocybin for treatment-resistant depression.
12-month trend
Fundamentals
Revenue, earnings and balance-sheet data for CMPS, updated as each quarter is reported.
Recent news
- Cybin Eyes Q4 Phase III Depression Data as Anxiety Program Advances - MarketBeatmarketbeat.com
- Cybin Sees Unusually High Options Volume (NASDAQ: HELP) - MarketBeatmarketbeat.com
- Compass Pathways: Built The FDA's Way, Valued At 0.57x Spravato's Sales - Seeking Alphaseekingalpha.com
- Cybin (NASDAQ: HELP) Upgraded at Wall Street Zen - MarketBeatmarketbeat.com
- Cybin (NASDAQ: HELP) Shares Down 4.5% - Here's What Happened - MarketBeatmarketbeat.com
- RevMed's pancreatic cancer drug nears European approval - Stat Newsstatnews.com
- Advancing Innovation in Mental Health: An Interview with Kabir Nath, CEO of Compass PathwaysPSA News
- Psychedelic Biotech in 2025: What’s Next? Featuring Florian Brand and Lars Wilde, Co-Founders of atai Life Sciences and Compass PathwaysPSA News